US8642064B2 - Bioabsorbable composite material - Google Patents
Bioabsorbable composite material Download PDFInfo
- Publication number
- US8642064B2 US8642064B2 US10/580,549 US58054904A US8642064B2 US 8642064 B2 US8642064 B2 US 8642064B2 US 58054904 A US58054904 A US 58054904A US 8642064 B2 US8642064 B2 US 8642064B2
- Authority
- US
- United States
- Prior art keywords
- bone regeneration
- regeneration material
- polymerisation
- monomer
- bioabsorbable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related, expires
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/0047—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L24/0073—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material with a macromolecular matrix
- A61L24/0084—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material with a macromolecular matrix containing fillers of phosphorus-containing inorganic compounds, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0036—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0042—Materials resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
- A61L27/46—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with phosphorus-containing inorganic fillers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
Definitions
- the present invention relates to a method of producing a self-hardening, bioabsorbable composite material, to a self-hardening, bioabsorbable composite material and to the use thereof in human and veterinary medicine, especially for bonding bone tissue, for filling bone defects and for producing implantable shaped pieces.
- Non-absorbable, or just partially absorbable, bone cements have been known for a long time and have been described in a large number of patents and scientific publications (e.g. G. Lewis, J. Biomed. Mater. Res. (Appl. Biomater.) 38 (1997) 155). They usually consist of a liquid component and a solid component. The liquid component consists of a liquid monofunctional methacrylic acid ester, with preference being given to the use of methyl methacrylate. A polymerisation activator, usually N,N-dimethyl-p-toluidine, is dissolved in that monomer.
- the solid component consists of a polymer which is swellable or soluble in the monomer, with copolymers of methyl methacrylate and of methylacrylate being most frequently used. Contained in the solid component is a polymerisation initiator, such as dibenzoyl peroxide. Curing of those bone cements is accomplished by means of the fact that the polymerisation activator dissolved in the monomer comes into contact with the polymerisation initiator contained in the solid component. As a result of. the action of the polymerisation activator, the polymerisation initiator decomposes immediately, giving rise to free radicals which immediately trigger polymerisation of the monofunctional monomer.
- a polymerisation initiator such as dibenzoyl peroxide
- multi-functional monomers those bone cements are no longer feasible because multi-functional monomers, by virtue of their polymerisation kinetics, polymerise extremely quickly and result in solid polymer networks which, even in the case of low degrees of crosslinking, can no longer be plastically deformed and therefore worked.
- a composite system similar to U.S. Pat. No. 5,814,682 is described in WO 87100058.
- a bone cement based on diacrylate or dimethacrylate comprises absorbable particles of bioceramic material or bioglass.
- the inorganic filler particles should have a pore volume of at least 0.2 ml/g because this is said to have a beneficial effect on the physical properties of the cement.
- a dental material capable of free radical polymerisation has been described in EP 0951896 A2. That dental material is characterised in that the filler is formed by a homogeneous mixture of a first part of the filler, which is coated with the polymerisation initiator, a second part of the filler, which is coated with the polymerisation activator, and a third part of the filler, which does not comprise any component of the initiator system.
- a biologically degradable composite material is disclosed in DE 19939403 A1.
- the composite material is formed by curing of the mixture of a liquid component A, which comprises at least one polymerisable, bioabsorbable monomer and, optionally, a bioabsorbable thickener, a solid component B, which consists of a bioabsorbable inorganic filler coated with a polymerisation initiator, and a solid component C, which is formed by a bioabsorbable inorganic filler coated with a polymerisation activator.
- the polymerisation activator and the polymerisation initiator are applied as coatings to the surface of fillers.
- the inorganic filler may be calcium carbonate, magnesium carbonate, calcium phosphate or hydroxyapatite; there is no requirement for interconnecting porosity.
- a dental material capable of free radical polymerisation having at least one polymerisable binder and at least one filler and comprising a redox initiator system for the free radical polymerisation, the system comprising an initiator and an activator.
- the filler is a homogeneous mixture of a first part of the filler, which is mixed with the initiator, a second part of the filler, which is mixed with the activator, and a third part of the filler, which does not comprise any component of the initiator system.
- interconnecting porosity is not required for the filler, with mention being made of, for example, quartz powder, glass-ceramic powder, glass powder, aluminium powder and silicon dioxide powder as preferred fillers.
- U.S. Pat. No. 5,814,681 relates to a restorative composition for hard tissue, comprising inorganic calcium phosphate powder; again, there is no requirement for interconnecting porosity.
- ⁇ ,- ⁇ ′-unsaturated compounds are provided as polymerisable monomers, the following warning being given for the polymerisation thereof:
- DE 44 35 860 A1 relates to production of a porous bone replacement material using an inorganic starting material, the porosity of which is not specified.
- a mixture of (a) a polymerisation product comprising polymerisation catalyst, (b) a liquid monomer comprising polymerisation accelerator and (c) inorganic material in the form of coarsely particulate granules is used as starting material.
- DE 100 18 394 A1 relates to production of porous calcium phosphate pieces obtained by sintering.
- the prior art of self-hardening, bioabsorbable composite materials is consequently characterised in that the polymerisation activators and polymerisation initiators required for crosslinking of the monomers are mixed in with the various components of the composite system or applied to the surface of those components.
- the present invention is accordingly based on the problem of being able to achieve even better control of the reaction of those accelerator components in the case of multi-functional monomers.
- the invention is furthermore based on the problem of providing a new, self-hardening, bioabsorbable composite material on the basis of di-, tri- or other multi-functional monomers as polymer network formers. It should be possible for that composite material to be made by mixing together individual composite constituents and/or previously produced partial mixtures or partial reaction products so as to form a pourable, injectable or spreadable mass and to cure automatically at room temperature after a processing time of from 2 to 5 minutes to form a solid composite.
- That immobilisation effect can be further increased, for example, when the initiator and activator, after having been immobilised using the particle-form, particulate or granular porous calcium phosphate, are dissolved away from the surfaces or outsides of the particles and allowed to remain solely inside pores, before adding the monomer.
- Partial dissolution of such a kind can be promoted, for example, by wetting with a solvent for just a short time and/or by not allowing the solvent to penetrate into the pores, for example by not evacuating the pores.
- constituents which modify the properties of the monomer, monomer mixture and/or composite material may be mixed in.
- constituents which modify the properties of the monomer, monomer mixture and/or composite material may be mixed in.
- Such constituents may be, for example, substances which alter the viscosity of the monomer, the monomer mixture and/or the mixture thereof with the bone regeneration material in a manner that is desirable for application.
- constituents which may be mixed in may be substances that alter the pH, pore-formers (so-called porogens), adhesion-imparting agents, colourants, contrast agents and/or pharmaceutical active ingredients.
- modifying constituents selected from the group: thickeners, diluents, polymeric fillers, porogens, pH-modifying substances, colourants and adhesion-imparting agents.
- the first partial amount and the second partial amount of the bone regeneration material may be used in a ratio of from 1:10 to 10:1 and/or the polymerisation initiator and the polymerisation activator may be immobilised with and/or in the respective partial amounts of the bone regeneration material in a ratio of from 1:10 to 10:1 (based on weight in each case).
- the bone regeneration material may be used in the form of powder or granules.
- a solution of the polymerisation initiator may be added to the bone regeneration material, the solution allowed to infiltrate the bone regeneration material and afterwards the bone regeneration material dried.
- a solution of the polymerisation initiator may be mixed with the amount (partial amount) of bone regeneration material, provided for the immobilisation thereof, in an amount of from 0.1 to 20% by weight (solid initiator based on bone regeneration material).
- an organic peroxide may be used as polymerisation initiator, preferably an organic peroxide selected from the group comprising dibenzoyl peroxide, lauroyl peroxide and acetone peroxide.
- a melt or a solution of the polymerisation activator may be added to the bone regeneration material, the melt or the solution allowed to infiltrate the bone regeneration material and afterwards the bone regeneration material dried.
- a solution of the polymerisation activator may be mixed with the amount (partial amount) of bone regeneration material provided for the immobilisation thereof in an amount of from 0.1 to 20% by weight (solid activator based on bone regeneration material).
- one or more polymerisation activators may be used which are selected from the group comprising N,N-bis(2-hydroxy-ethyl)-p-toluidine, N,N-dimethyl-p-toluidine, N,N-dimethyl-N,N-aniline, ascorbic acid and barbituric acid.
- the polymerisation initiator may be used in the form of a solution and/or the polymerisation activator may be used in the form of a solution and the solution(s) allowed to be drawn up by the bone regeneration material completely or as far as possible and the excess not drawn up removed before step (iii).
- an alkaline earth metal phosphate and/or an alkali metal/alkaline earth metal phosphate especially an alkaline earth metal orthophosphate and/or alkali metal/alkaline earth metal orthophosphate, preferably a bone regeneration material which is selected from the group comprising alpha-tricalcium phosphate, beta-tricalcium phosphate, calcium-deficient carbonate-containing hydroxyapatite, octacalcium phosphate, magnesium phosphate, calcium hydrogen phosphate, calcium/sodium orthophosphate and calcium pyrophosphate.
- a bone regeneration material which is the same as or different from that for immobilisation of the polymerisation activator. That free choice corresponds in that respect to the prior art, for example according to U.S. Pat. No. 5,814,681 column 3 lines 53-55.
- the bone regeneration material for immobilisation of the initiator may differ from the bone regeneration material for immobilisation of the activator in its chemical and/or mineralogical nature.
- an interconnectingly porous bone regeneration material especially calcium phosphate, having the following characteristic data may be used:
- an interconnectingly porous bone regeneration material especially calcium phosphate, having a pore volume, accessible to the polymerisation initiator and/or the polymerisation activator, of 0.4 cm 3 /g or more, and especially from 0.4 to 3.3 cm 3 /g, while retaining the integrity of the particles of the bone regeneration material.
- the bone regeneration material especially calcium phosphate
- the bone regeneration material may be used in crystalline, partly crystalline, glassy or amorphous form.
- constituents which are biocompatible and which modify the properties of the regeneration material may be mixed in with the bone regeneration material.
- a multi-functional oligomer having terminal methacrylate groups especially an oligomer of lactic acid and/or glycolic acid and/or delta-hydroxyvaleric acid and/or epsilon-hydroxycaproic acid and/or trimethylene carbonate.
- the monomer or monomer mixture may be used together with an adhesion-imparting agent, preferably a hydroxyl-group-containing adhesion-imparting agent, especially methacrylic acid 2-hydroxyethyl ester.
- an adhesion-imparting agent preferably a hydroxyl-group-containing adhesion-imparting agent, especially methacrylic acid 2-hydroxyethyl ester.
- the monomer or monomer mixture may be used together with a viscosity-modifying substance or thickener, preferably dianhydro-D-glucitol-bis(poly-D,L-lactide).
- the problem on which the invention is based is solved by a self-hardened bioabsorbable composite material which can be produced by
- the weight ratio of bone regeneration material: monomer or monomer mixture may be from 4:6 to 8:2.
- the composite material according to the invention may be obtainable by a method according to the invention.
- the problem on which the invention is based is solved by a self-hardening bioabsorbable composite material in the form of a set consisting of or comprising
- the weight ratio of bone regeneration material: monomer or monomer mixture may be from 4:6 to 7:3.
- the composite material according to the invention may be obtainable in the form of a set by the method according to the invention, in the same manner as each of its components (i), (ii) and (iii).
- the problem on which the invention is based is solved by use of a self-hardened composite material according to the invention in machine-production of implants in the form of shaped pieces of standardised dimensions for bone regeneration or of implants that are individual to a patient.
- a polymerisation initiator in a first partial step (I), is accordingly immobilised in an interconnecting pore system of a first partial amount of a bioabsorbable bone regeneration material, for example a calcium phosphate, used in producing the self-hardening, bioabsorbable composite material.
- a polymerisation activator is immobilised in the interconnecting pore system of a second partial amount of the bioabsorbable bone regeneration material, for example a calcium phosphate, used in producing the self-hardening, bioabsorbable composite material.
- the first partial amount and the second partial amount are in a ratio of from 1:10 to 10:1, and the polymerisation initiator and the polymerisation activator are in a ratio of from 1:10 to 10:1 (based on weight in each case).
- the components according to (I) and (II) are homogeneously mixed with a liquid or paste-form monomer or monomer mixture capable of forming a biocompatible, bioabsorbable polymer network and, optionally, further constituents which modify the properties of the monomer.
- Such property-modifying constituents may be, for example, substances which alter the viscosity of the monomer, monomer mixture and/or the mixture thereof with the bone regeneration material in a manner that is desirable for application.
- constituents which may be mixed in may be pH-modifying substances, pore-formers (so-called porogens), adhesion-imparting agents, colourants, contrast agents and/or pharmaceutical active ingredients.
- pH-modifying substances such as pH-modifying substances, pore-formers (so-called porogens), adhesion-imparting agents, colourants, contrast agents and/or pharmaceutical active ingredients.
- immobilisation is understood to be, preferably, the temporary fixing of a reaction-accelerating substance in the interconnecting pore or channel system of suitable carrier particles, which are themselves substantially non-reactive, of bone regeneration material, e.g. calcium phosphate.
- suitable carrier particles which are themselves substantially non-reactive, of bone regeneration material, e.g. calcium phosphate.
- size of the carrier particles reference may be made to the prior art.
- further principles involving delayed active ingredient release which are known from drug delivery systems; cf., for example, Schmidt et al. in J. Controlled Release, 37 (1995) 83-94 and Cimbollek et al. in Antimicrob. Agents Chemother., 40 (1996) 1432-1437.
- the decisive factor for suitability for use is a release rate which is appropriate to solving the problem according to the invention.
- interconnectingly porous bone regeneration materials e.g. calcium phosphates, in which at least one polymerisation initiator is immobilised
- interconnectingly porous bone regeneration materials e.g. calcium phosphates, in which at least one polymerisation activator is immobilised
- the resulting mixtures are, surprisingly, capable of being worked at room temperature over a period of from 2 to 10 minutes. During that time, the mixtures are plastically deformable and injectable, pourable and spreadable. After that, curing occurs suddenly.
- the processing time of the self-hardening, bioabsorbable composite material is governed by delayed diffusion out of the pore systems of the porous bone regeneration materials such as, for example, calcium phosphates. It is furthermore assumed that the pore diameter and channel diameter of the interconnecting pore system and the size of the interconnecting pore systems have an influence on the diffusion, governed by the particle size distribution of the bioabsorbable bone regeneration materials such as, for example, calcium phosphates.
- the diffusion rate is additionally influenced by temperature.
- bone regeneration material is understood to be any bioabsorbable material, suitable for bone regeneration, from the group of the alkaline earth metal and alkali metal-alkaline earth metal phosphates, especially calcium phosphates.
- the specific material composition of the bioabsorbable bone regeneration material e.g. calcium phosphate, is of subordinate importance for the self-hardening, bioabsorbable composite material according to the invention, in comparison to its internal surface and pore structure.
- the polymerisation initiator in dissolved form is mixed with a first partial amount of the bioabsorbable regeneration material such as calcium phosphate in a relative amount of, for example, from 0.1 to 20% by weight and the concentration of its solution is so adjusted that the bone regeneration material draws up the solution of the polymerisation initiator into its interconnecting pore system completely.
- the bone regeneration material is then dried and so is available for further production steps, such as packaging and sterilisation. After the bone regeneration material soaked with the solution of the polymerisation initiator has been dried, the initiator fills the pore systems of the bone regeneration material entirely or at least partly.
- Solvents suitable for the polymerisation initiator are various ketones, preferably acetone. They are distinguished, on the one hand, by good dissolution characteristics and, on the other hand, by good drying characteristics and can be removed completely from the pore system of the bone regeneration material, for example the calcium phosphate, without impairing the reaction characteristics of the polymerisation initiator.
- the polymerisation activator is immobilised in analogous manner, by dissolving it in an organic solvent or by melting it, and mixing it, for example in an amount of from 0.1 to 20% by weight based on a second partial amount of the bone regeneration material, e.g. calcium phosphate, with the latter.
- the concentration of the solution in that case is so adjusted that the latter is likewise drawn up into the pore system of the bone regeneration material completely.
- the bone regeneration material is then dried and is available for further production steps, such as packaging and sterilisation. After the bone regeneration material soaked with the solution of the polymerisation activator has been dried, the activator fills the pore systems of the bone regeneration material entirely or at least partly.
- Suitable solvents are to be found, for example, in the prior art.
- Suitable solvents for the polymerisation activator are various alcohols or ketones, preferably ethanol. They are distinguished, on the one hand, by good dissolution characteristics and, on the other hand, by good drying characteristics and can be removed completely from the micropore system of the calcium phosphate without impairing the reaction characteristics of the polymerisation activator.
- Suitable bone regeneration materials such as, for example, calcium phosphates are bioabsorbable materials that have been successfully used for bone regeneration from the group of alkaline earth metal phosphates and alkali metal-alkaline metal earth phosphates, especially their orthophosphates, such as alpha-tricalcium phosphate or beta-tricalcium phosphate, magnesium phosphate, calcium/sodium orthophosphate, calcium-deficient, carbonate-containing hydroxyapatite, octacalcium phosphate, calcium hydrogen phosphate and/or calcium pyrophosphate.
- the first partial amount of the bone regeneration material used for immobilisation of the polymerisation initiator may be chemically and mineralogically identical to the second partial amount for immobilisation of the polymerisation activator. However, the two partial amounts may also differ in their chemical or mineralogical nature if that does not have a negative effect but rather a beneficial effect on the properties of the self-hardening, bioabsorbable composite material.
- the interconnecting pore system of the bioabsorbable bone regeneration materials e.g. calcium phosphates
- the interconnecting pore system of the bioabsorbable bone regeneration materials has pore cross-sections preferably in the range from 0.1 to 100 ⁇ m, more preferably in the range from 0.1 to 10 ⁇ m, the particle size distribution of the bioabsorbable bone regeneration materials having an effect on the release of the polymerisation initiator and the polymerisation activator such that, with increasing particle size, the speed of release and, as a result, the speed of polymerisation are slowed down.
- particle sizes (as d 50 values) in a range from 1 to 500 ⁇ m, preferably from 5 to 300 ⁇ m have been found to be suitable for the desired reaction times.
- the bone regeneration material e.g.
- calcium phosphate may be used in crystalline, glassy crystalline or amorphous form.
- the crystalline form of the material is of subordinate importance in comparison to the interconnecting pore structure and particle size distribution of the bone regeneration material particles.
- the interconnecting pore structure of the bone regeneration material advantageously has a high internal surface area with small pore/channel diameters.
- a preferred embodiment has a BET surface area of at least 0.1 m 2 /g with average pore diameters in the range from 0.1 to 20 ⁇ m.
- biocompatible, property- and/or structure-modifying constituents e.g. silicon compounds
- the bone regeneration materials e.g. calcium phosphates
- the polymer content of the self-hardening, bioabsorbable composite material is produced from a liquid or paste-form monomer capable of forming a biocompatible, bioabsorbable polymer network or from a mixture of such monomers and by polymerisation thereof using the above-indicated polymerisation initiators and polymerisation activators.
- the liquid or paste-form monomer or monomer mixture consists of a material from the group of multi-functional, methacrylate-terminated oligomers, preferably based on lactic acid and/or glycolic acid and/or 8-hydroxyvaleric acid and/or ⁇ -hydroxy-caproic acid and/or trimethylene carbonate.
- the self-hardening, bioabsorbable composite material is formed from 40 to 80% by weight of a bone regeneration material, e.g. calcium phosphate or calcium phosphate mixture, and from 20 to 60% by weight of a liquid or paste-form, bioabsorbable, multi-functional monomer or monomer mixture and, optionally, further constituents which modify the properties of the monomer.
- a bone regeneration material e.g. calcium phosphate or calcium phosphate mixture
- Its formulation consists of a mixture of at least a starting component A, consisting of an interconnectingly porous bone regeneration material, e.g. calcium phosphate, in the pore system of which a polymerisation initiator has been immobilised, a starting component B, consisting of an interconnectingly porous bone regeneration material, e.g.
- calcium phosphate in the pore system of which a polymerisation activator has been immobilised, and a starting component C, consisting of a liquid or paste-form, bioabsorbable, multi-functional monomer or a corresponding monomer mixture and, optionally, further constituents which modify the properties of the monomer or monomer mixture.
- Such property-modifying constituents are, for example, substances which alter the viscosity of the monomer, monomer mixture and/or the mixture thereof with the bone regeneration material in a manner that is desirable for processing and application.
- suitable viscosity-altering substances are oligomeric or polymeric derivatives of alpha-hydroxycarboxylic acids, especially of lactic and glycolic acid and also copolymers thereof and/or oligo- and poly-ethylene glycols.
- Dianhydro-D-glucitol-bis(poly-D,L-lactide) having a molecular weight of about 17,000 g/mol is an especially suitable viscosity-increasing substance.
- Further property-modifying constituents are substances which are water-soluble or which react with water to form water-soluble resultant products and which bring about a pH change in a water-containing medium, as a result of which the decomposition rate of the self-hardened composite material can be modified.
- Property-modifying constituents are also water-soluble substances which, in particulate form, are mixed in with the monomer, monomer mixture and/or mixture thereof with the bone regeneration material and which, after introduction of the self-hardened composite material into a water-containing medium, for example a bone defect, are dissolved out from the composite material, whereby additional pores are formed.
- adhesion-imparting agents which improve the adhesion between the self-hardened composite material and the natural tissue, especially hard tissue.
- adhesion-imparting agents are especially those which have free hydroxyl groups, such as, for example, methacrylic acid 2-hydroxyethyl ester.
- Property-modifying constituents are also colourants and/or contrast agents, which are used, for example, for facilitating visualisation of the composite material in the body.
- Further property-modifying constituents are pharmaceutical active ingredients or active ingredient mixtures which are released from the composite material after implantation and may be used for local therapeutic or prophylactic treatment of the tissue located in the vicinity of the composite material. Examples of active ingredients that may be mixed in are antibiotics, anti-inflammatories, proteinogenic growth factors or cancerostatics.
- the self-hardening, bioabsorbable composite material is produced by polymerisation of a mixture of a starting component A, consisting of an interconnectingly porous bone regeneration material, e.g. calcium phosphate, in the pore system of which a polymerisation initiator has been immobilised, a starting component B, consisting of an interconnectingly porous bone regeneration material, e.g. calcium phosphate, in the pore system of which a polymerisation activator has been immobilised, and a starting component C, consisting of a liquid or paste-form, bioabsorbable, multi-functional monomer or a multi-functional monomer mixture.
- further constituents which modify the properties of the monomer, of the monomer mixture or of the self-hardening, bioabsorbable composite material itself may be included.
- the self-hardening, bioabsorbable composite material is formed from 40 to 80% by weight of bone regeneration material, e.g. calcium phosphate, and from 20 to 60% by weight of a liquid or paste-form, bioabsorbable, multi-functional monomer or a multi-functional monomer mixture and, optionally, further constituents which modify the properties of the monomer.
- bone regeneration material e.g. calcium phosphate
- the self-hardening, bioabsorbable composite material is used in two different ways depending on the procedure used as part of bone healing.
- use as a self-hardening, bioabsorbable bone adhesive is possible whereas, in the case of in vitro polymerisation, implants can be produced from compact pieces of composite by suitable processing methods.
- the bioabsorbable bone adhesive is used preferably for the fixing of comminuted fractures in regions of the skeleton that are not loaded or that are subject to low loading and may, when combined with osteosynthesis measures, be used in the entire region of the skeleton.
- Cured materials produced using the bone adhesive according to the invention are suitable for producing implants for bone regeneration. They may be machined very well and with a high degree of accuracy. It is possible to produce shaped pieces of standardised dimensions and also shaped pieces that are individual to a patient, which may be used as bioabsorbable implants as part of bone healing.
- bioabsorbable composite material For producing the self-hardening, bioabsorbable composite material there are used three starting components A, B and C and, optionally, adhesion-imparting agents and thickeners suitable for improving the processing properties and/or the physical properties of the self-hardening, bioabsorbable composite material:
- Starting component A Pure-phase ⁇ -tricalcium phosphate, particle size ⁇ 50 ⁇ m, 0.2 m 2 /g BET surface area, 90% of the pores are in the diameter range 2 ⁇ 1 ⁇ m and containing immobilised polymerisation initiator
- Starting component B Pure-phase ⁇ -tricalcium phosphate, particle size ⁇ 50 ⁇ m, 0.2 m 2 /g BET surface area, 90% of the pores are in the diameter range 2 ⁇ 1 ⁇ m and containing immobilised polymerisation activator
- Starting component C Bifunctional monomer dianhydro-D-glucitol- bis[(oligo-L-lactyl methacrylate] (theoretically 2 L-lactic acid units per hydroxyl group of the dianhydro-D-glucitol)
- Adhesion-imparting agent Methacrylic acid 2-hydroxyethyl ester (HEMA) Thickener: Dianhydro-D-glucitol-poly-D,L-lactide
- the self-hardening, bioabsorbable composite materials R1 to R4 were prepared (see Tab. 1). These have a processing time of from 2 to 10 minutes and they then cure within from 30 to 60 seconds.
- the self-hardening, bioabsorbable composite materials were used to carry out adhesion tests using defatted cattle bones.
- square plates of bone (7 ⁇ 7 ⁇ 3 mm) were bonded to the middle of rectangular plates of bone (20 ⁇ 10 ⁇ 3 mm).
- the tensile shear strength was determined using a tensile testing machine from the Instron company.
- cylindrical test specimens (height 10 mm, diameter 10 mm) were prepared from the self-hardening, bioabsorbable composite materials using silicone rubber moulds. The compressive strength of those test specimens was likewise determined using a tensile testing machine from the Instron company (see Tab. 2).
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10355992.2 | 2003-11-22 | ||
DE10355992A DE10355992A1 (de) | 2003-11-27 | 2003-11-27 | Bioresorbierbares Kompositmaterial |
DE10355992 | 2003-11-27 | ||
PCT/EP2004/013388 WO2005051443A1 (de) | 2003-11-27 | 2004-11-25 | Bioresorbierbares kompositmaterial |
Publications (2)
Publication Number | Publication Date |
---|---|
US20070254011A1 US20070254011A1 (en) | 2007-11-01 |
US8642064B2 true US8642064B2 (en) | 2014-02-04 |
Family
ID=34625439
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/580,549 Expired - Fee Related US8642064B2 (en) | 2003-11-27 | 2004-11-25 | Bioabsorbable composite material |
Country Status (6)
Country | Link |
---|---|
US (1) | US8642064B2 (ja) |
EP (1) | EP1687040B1 (ja) |
JP (1) | JP2007512063A (ja) |
CN (1) | CN100502954C (ja) |
DE (1) | DE10355992A1 (ja) |
WO (1) | WO2005051443A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9457124B2 (en) | 2012-07-20 | 2016-10-04 | Heraeus Medical Gmbh | Paste-like bone cement |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10032220A1 (de) * | 2000-07-03 | 2002-01-24 | Sanatis Gmbh | Magnesium-ammonium-phosphat-Zemente, deren Herstellung und Verwendung |
US7273523B2 (en) | 2002-06-07 | 2007-09-25 | Kyphon Inc. | Strontium-apatite-cement-preparations, cements formed therefrom, and uses thereof |
EP1742680B1 (en) | 2004-04-27 | 2012-10-24 | Kyphon SÀRL | Bone substitute compositions and method of use |
WO2006073711A2 (en) * | 2005-01-06 | 2006-07-13 | Kuros Biosurgery Ag | Use of a matrix comprising a contrast agent in soft tissues |
EP1833522B1 (en) * | 2005-01-06 | 2016-06-22 | Kuros Biosurgery AG | Supplemented matrices for the repair of bone fractures |
US8575101B2 (en) | 2005-01-06 | 2013-11-05 | Kuros Biosurgery Ag | Supplemented matrices for the repair of bone fractures |
GB0514076D0 (en) * | 2005-07-08 | 2005-08-17 | Depuy Int Ltd | Bioactive bone cement composition |
US7651701B2 (en) * | 2005-08-29 | 2010-01-26 | Sanatis Gmbh | Bone cement composition and method of making the same |
DE102006010075B4 (de) * | 2006-03-04 | 2010-01-28 | Ivoclar Vivadent Ag | Verfahren zur Herstellung von im Dentalbereich einsetzbaren Kunststoffformteilen |
US7754005B2 (en) * | 2006-05-02 | 2010-07-13 | Kyphon Sarl | Bone cement compositions comprising an indicator agent and related methods thereof |
US7507286B2 (en) * | 2006-06-08 | 2009-03-24 | Sanatis Gmbh | Self-foaming cement for void filling and/or delivery systems |
WO2008154505A1 (en) * | 2007-06-08 | 2008-12-18 | The Regents Of The University Of California | Biodegradable synthetic bone composites |
US7968616B2 (en) * | 2008-04-22 | 2011-06-28 | Kyphon Sarl | Bone cement composition and method |
FR2942723B1 (fr) * | 2009-03-05 | 2011-06-10 | Teknimes | Ciment pour comblement osseux |
ES2882852T3 (es) | 2011-03-16 | 2021-12-02 | Kuros Biosurgery Ag | Formulación farmacéutica para la utilización en la fusión espinal |
EP2529764A1 (de) * | 2011-05-31 | 2012-12-05 | Curasan AG | Biologisch degradierbares kompositmaterial |
EP2751045A4 (en) * | 2011-08-31 | 2015-04-22 | Bonestone Ltd | MAGNESIUM PHOSPHATE BIOMATERIALS |
DE102012014702A1 (de) * | 2012-07-25 | 2014-01-30 | Heraeus Medical Gmbh | Pastenförmiger Knochenzement |
CN107343965B (zh) * | 2016-05-06 | 2020-04-24 | 中国科学院化学研究所 | 一种骨粘合剂及其制备方法 |
CN109876191B (zh) * | 2017-07-15 | 2020-04-03 | 深圳市立心科学有限公司 | 可吸收的生物医用复合材料及其制备方法 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4192021A (en) * | 1976-05-12 | 1980-03-11 | Batelle-Institut e.V. | Bone replacement or prosthesis anchoring material |
US4373217A (en) * | 1979-02-16 | 1983-02-15 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Implantation materials and a process for the production thereof |
WO1987000058A1 (en) | 1985-07-05 | 1987-01-15 | Werther Lusuardi | Bone cement |
US5650108A (en) | 1994-10-06 | 1997-07-22 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Porous bone replacement materials |
US5814681A (en) | 1994-10-13 | 1998-09-29 | Kuraray Co., Ltd. | Restorative composition for hard tissue and dispensing apparatus therefor |
DE19939403A1 (de) | 1999-08-19 | 2001-02-22 | Fzmb Forschungszentrum Fuer Me | Biologisch abbaubares Kompositmaterial |
US6281271B1 (en) | 1998-04-24 | 2001-08-28 | Ivoclar Ag | Radically polymerizable dental material |
US6340648B1 (en) | 1999-04-13 | 2002-01-22 | Toshiba Ceramics Co., Ltd. | Calcium phosphate porous sintered body and production thereof |
US20020120033A1 (en) | 2000-08-11 | 2002-08-29 | Weitao Jia | Dental/medical compositions comprising degradable polymers and methods of manufacture thereof |
-
2003
- 2003-11-27 DE DE10355992A patent/DE10355992A1/de not_active Withdrawn
-
2004
- 2004-11-25 WO PCT/EP2004/013388 patent/WO2005051443A1/de active Application Filing
- 2004-11-25 EP EP04798078A patent/EP1687040B1/de not_active Not-in-force
- 2004-11-25 JP JP2006540382A patent/JP2007512063A/ja active Pending
- 2004-11-25 CN CNB2004800352880A patent/CN100502954C/zh not_active Expired - Fee Related
- 2004-11-25 US US10/580,549 patent/US8642064B2/en not_active Expired - Fee Related
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4192021A (en) * | 1976-05-12 | 1980-03-11 | Batelle-Institut e.V. | Bone replacement or prosthesis anchoring material |
US4373217A (en) * | 1979-02-16 | 1983-02-15 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Implantation materials and a process for the production thereof |
WO1987000058A1 (en) | 1985-07-05 | 1987-01-15 | Werther Lusuardi | Bone cement |
US5650108A (en) | 1994-10-06 | 1997-07-22 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Porous bone replacement materials |
US5814681A (en) | 1994-10-13 | 1998-09-29 | Kuraray Co., Ltd. | Restorative composition for hard tissue and dispensing apparatus therefor |
US6281271B1 (en) | 1998-04-24 | 2001-08-28 | Ivoclar Ag | Radically polymerizable dental material |
US6340648B1 (en) | 1999-04-13 | 2002-01-22 | Toshiba Ceramics Co., Ltd. | Calcium phosphate porous sintered body and production thereof |
DE19939403A1 (de) | 1999-08-19 | 2001-02-22 | Fzmb Forschungszentrum Fuer Me | Biologisch abbaubares Kompositmaterial |
US20020120033A1 (en) | 2000-08-11 | 2002-08-29 | Weitao Jia | Dental/medical compositions comprising degradable polymers and methods of manufacture thereof |
Non-Patent Citations (5)
Title |
---|
"BET" surface area (http://en.wikipedia.org/wiki/BET-theory). * |
"BET" surface area (http://en.wikipedia.org/wiki/BET—theory). * |
http://en.wikipedia.org/wiki/Chlorophyll. * |
Machine translation for DE 199 39 403 A1 (attached as NPL). * |
Merriam-Webster Online Dictionary: "prophylaxis" (http://www.merriam-webster.com/dictionary/prophylaxis) and "prevent" (http://www.merriam-webster.com/dictionary/prevent). * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9457124B2 (en) | 2012-07-20 | 2016-10-04 | Heraeus Medical Gmbh | Paste-like bone cement |
US9987392B2 (en) | 2012-07-20 | 2018-06-05 | Heraeus Medical Gmbh | Kit for preparing a paste-like bone cement |
Also Published As
Publication number | Publication date |
---|---|
DE10355992A1 (de) | 2005-06-30 |
CN100502954C (zh) | 2009-06-24 |
CN1886160A (zh) | 2006-12-27 |
WO2005051443A1 (de) | 2005-06-09 |
EP1687040A1 (de) | 2006-08-09 |
EP1687040B1 (de) | 2013-02-20 |
JP2007512063A (ja) | 2007-05-17 |
US20070254011A1 (en) | 2007-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8642064B2 (en) | Bioabsorbable composite material | |
CA2614527C (en) | Bone cement composition | |
AU2004268013B2 (en) | Hydrogel porogens for fabricating biodegradable scaffolds | |
US6160033A (en) | Process for producing bone cement containing active substances | |
US5650108A (en) | Porous bone replacement materials | |
JP4975934B2 (ja) | 注射可能な骨鉱物置換材料 | |
JP5698075B2 (ja) | ペースト様骨セメント | |
US20200046874A1 (en) | Compositions for tissue hemostasis, repair and reconstruction | |
WO2013165333A1 (en) | Bone putty | |
JP2010046249A (ja) | 硬組織補填材 | |
Moussi et al. | Injectable macromolecule-based calcium phosphate bone substitutes | |
EP1086711B1 (en) | Ceramic-polymer composites | |
KR101019741B1 (ko) | 골대체용 복합재료의 제조방법 | |
US6872387B1 (en) | Three-dimensional hydrogel/cell system | |
JP2014124416A (ja) | 骨再生材料キット、ペースト状骨再生材料、骨再生材料及び骨接合材 | |
SE2250155A1 (en) | Putty formultion comprising macroporous hydroxyapatite composition and methods of making such |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: CURASAN AG, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SCHNABELRAUCH, MATTHIAS;VOGT, SEBASTIAN;REIF, DIETER;SIGNING DATES FROM 20060720 TO 20060817;REEL/FRAME:019184/0759 Owner name: CURASAN AG, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SCHNABELRAUCH, MATTHIAS;VOGT, SEBASTIAN;REIF, DIETER;REEL/FRAME:019184/0759;SIGNING DATES FROM 20060720 TO 20060817 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
FEPP | Fee payment procedure |
Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
LAPS | Lapse for failure to pay maintenance fees |
Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20220204 |